Moreover, miR-483-5p is associated with future onset of both diabetes and cardiovascular disease (Gallo et al., 2018) and increases hepatic LDL receptor levels by inhibiting PCSK9 production (Dong et al., 2020). Here, LDLR is linked to diabetes mellitus.